First Patient Dosed in Global Pivotal Phase 3 Clinical Trial for BioNTech and DualityBio’s B7-H3 ADC DB-1311/BNT324 in Metastatic Castration-Resistant Prostate Cancer

2026 ESMO Breast Cancer | Presentation of Preliminary Clinical Data for DualityBio and BioNTech’s Next-Generation TROP2 ADC Sacituzumab Drozuntecan in First-Line Advanced TNBC

DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer